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hospital mortality, length of stay, resource use and the TISS 28,
a tool developed to assess workload of hospital staff for inten-
sive care patients. Economic aspects were assessed using pub-
lished average daily costs as approximation of item costs.
RESULTS: A total of 62% of ARDS patients were male, median
age of 55 years, and most patients with socioeconomic data were
either working or in retirement. The main predisposing events
for ARDS were sepsis (51%), pneumonia (35%) and trauma or
surgery (28%). During the initial hospitalization 70 patients
(36%) died. Overall length of hospital stay was 31 ± 41 (mean
± SD) days, with most days spent in the Intensive Care Unit (ICU;
20 ± 21 days) and General Ward (8 ± 22 days). On average
patients were artiﬁcially ventilated for 16 ± 14 days and intu-
bated for 16 ± 15 days. As assessed by the TISS 28, the average
daily TISS score was 33 ± 10, which corresponds to a nursing
time of 5.9 hours per day, and mainly related to basic activities
(12 ± 3), ventilatory support (6 ± 2) and cardio-vascular support
(10 ± 5). Average overall hospital costs amount to 38,263 USD
per patient. CONCLUSIONS: ARDS is a severe condition with
a high mortality during inpatient treatment. Patients are treated
mainly in the ICU requiring intensive artiﬁcial ventilation and
high nursing workload, thereby resulting in high treatment cost.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD)
is a debilitating disease. The purpose of this study was to char-
acterise the association between various clinical and quality of
life outcome parameters typically used to characterise respira-
tory illnesses, and utility, as measured by the EQ5Dindex.
METHODS: Data were abstracted from the Health Outcomes
Data Repository (HODaR), an ongoing survey of patients in a
UK region that included the EQ5D and the SF36 and the St.
George’s Respiratory Questionnaire (StGRQ). Detailed lung
function data (LFD) were also available on the same patients for
the 12-year period. Generalised linear models were used to esti-
mate utility from predictor variables and goodness of ﬁt was
ascertained by the proportion of predictions lying within 0.03
utility units. RESULTS: Complete data were available on 444
subjects. A multinomial regression model mapped the clinical
data from 315 (71%) of these subjects to EQ5Dindex and the
resulting model was then applied to an independent set of 
129 (29%) subjects. In the 315 subjects, 40%, 41% and 52%
of predictions were within 0.03 units when using i) the SF36
alone, ii) the SF36 with LFD and iii) the SF36 with LFD and St.
George’s data, respectively. The same models applied to the test
data set resulted in 33%, 33% and 29% of predictions within
0.03 units, respectively. For subjects with moderate to severe
COPD (based on the GOLD classiﬁcation) 49%, 53% and 79%
of predictions were within 0.03 units, respectively. The corre-
sponding ﬁgures for none or mild COPD (GOLD classiﬁcation)
were 47%, 49% and 86%, respectively. CONCLUSIONS: It was
possible to reliably model the EQ5Dindex from the SF36 in respi-
ratory disease; however, models that included the lung function
data provided a marginal improvement, and the availability of
the StGRQ conferred further improvement within the construc-
tion data set.
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OBJECTIVES: Analize the correlation among different ques-
tionnaires of quality of life and FEV1 in patients with COPD.
METHODS: Cross-sectional study of 126 patients with COPD
controlled in a primary care setting. Non-random sample.
Patients were asked to ﬁll in ﬁve questionnaires of quality of life
(Euroquol, Coop-Wonca vignettes -CW-, Nottingham Health
Proﬁle -NHP-, Saint George Respiratory Questionnaire -SGRQ-
and de Basal Dyspnoea Index -BDI-) and they also performed a
forced spirometry. Other variables measured were: age, sex,
study level, marital status, comorbidity, and prescribed treat-
ment. RESULTS: A total of 88.9% males, age (mean + std) 68.5
+ 8.5 years, 32% illiterates, 87% married; 70% received bron-
chodilator treatment; 74% had at least another comorbid con-
dition; FEV 1 57.2% + 19.5%. Quality of life was moderately
affected: Euroquol visual scale (6.2 + 2.1), C-W physical activ-
ity (3.6 + 0.9), C-W feelings (2.1 + 1.1), C-W daily activities (2.2
+ 0.1), C-W social activities (1.8 + 1.3), C-W change in health
status (2.5 + 0.8), C-W health status (3.5 + 0.9), C-W pain (2.5
+ 1.3), C-W social support (2.0 + 1.0), C-W quality of life (2.4
+ 0.7), NHP total (31.5.2 + 22.8), SGRQ (36.4 + 21.6), BDI-
functional impairment (2.9 + 0.9), BDI-magnitude of work (2.9
+ 0.9), BDI-magnitude of effort (2.9 + 0.9). Spearman correla-
tion coefﬁcient was statistically signiﬁcant among all the QOL
questionnaires excepted between Euroqol and BDI-magnitude of
work. This correlation was mild-moderate (r < 0.5). FEV1 cor-
related with BDI, SGRQ, C-W physical activity, C-W daily activ-
ities, C-W health status (r = 0.41; r = 0.38, r = -0.19, r = -0.27,
r = -0–21, respectively). Correlation was moderate-high among
BDI, NHP, SGRQ, and COOP-Wonca Vignetes (r > 0.5). CON-
CLUSIONS: Quality of life in patients with COPD is slightly cor-
related with functional status (specially speciﬁc respiratory
questionnaires and several vignettes of COOP-WONCA ques-
tionnaire). There is a good correlation between generic and spe-
ciﬁc QOL questionnaires in patients with COPD.
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OBJECTIVE: To assess the discriminative properties of the EQ-
5D with respect to COPD severity according to GOLD in a large
multinational study. METHODS: Baseline EQ-5D Visual Ana-
logue Scale (VAS) scores, EQ-5D utilities and SGRQ scores were
obtained from a subset of patients in the UPLIFT trial, a 4-yr
placebo-controlled trial of tiotropium in COPD patients aged ≥
40, FEV1% pred < 70, FEV1/FVC £ 70% and ≥10 pack years
of smoking to assess the rate of decline in FEV1. RESULTS:
1,235 patients (mean post bronchodilator FEV1% pred 48.77)
from 13 countries completed the EQ-5D. EQ-5D VAS and utility
scores differed signiﬁcantly between GOLD stages 2, 3 and 4,
also after correction for age, sex, smoking, BMI and co-
morbidity (p < 0.001). Mean (SD) EQ-5D VAS scores in GOLD
stages 2, 3 and 4 were 68 (16), 62 (17) and 58 (16), respectively.
Mean (SD) utilities were 0.79 (0.20) in GOLD 2, 0.75 (0.21) in
GOLD 3 and 0.65 (0.23) in GOLD 4. Effect sizes for the dif-
ference in utilities between GOLD 3 and 4 were more than twice
as high as for the difference between 2 and 3. Gender, post-
